Tear and blood molecules may unlock secrets of eye allergies
NCT ID NCT07385495
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares small molecules called microRNAs in the tears and blood of 40 people with allergic conjunctivitis versus healthy individuals. The goal is to find patterns that could help diagnose the condition and reveal new targets for treatment. Participants are aged 5 to 30 and provide samples during active allergy symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could identify new biomarkers to better diagnose allergic conjunctivitis and point toward future treatments.
- What could go wrong
- This is a small, early-stage observational study, not testing a treatment. The findings may not lead to new therapies or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include subjects aged 5 to 30 years with a clinical diagnosis of allergic conjunctivitis, as well as age-matched healthy controls. Participants will be recruited from a specialized ophthalmology center. Subjects with allergic conjunctivitis must present active ocular symptoms at the time of enrollment, while healthy controls must have a clinically normal ocular surface and no history of active ocular disease. All participants or their legal guardians will provide written informed consent, with assent obtained from minors when applicable.
- Ages
-
5 to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Subjects with Allergic Conjunctivitis: * Age between 5 and 30 years. * Clinical diagnosis of allergic conjunctivitis. * Presence of active ocular symptoms at the time of sample collection. * Positive skin prick test. * Written informed consent signed by the participant or parent/legal guardian, -with assent when applicable. Healthy Controls: * Age between 5 and 30 years. * Clinically healthy subjects with a normal ocular surface. * No evidence of active ocular disease. * Written informed consent signed by the participant or parent/legal guardian, with assent when applicable. Exclusion Criteria * Subjects with Allergic Conjunctivitis: * History of infectious disease within 2 months prior to sample collection. * Presence of active systemic allergic diseases (e.g., asthma, active dermatitis). * Chronic degenerative or autoimmune diseases. * Use of topical immunosuppressive treatment within 2 months prior to sample collection. * Use of systemic immunosuppressive therapy. Healthy Controls: -History of infectious disease within 2 months prior to sample collection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Conjunctivitis, allergic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro
Mexico City, Mexico City, 06800, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.